241 related articles for article (PubMed ID: 11283861)
1. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy.
Boni C; Penna A; Ogg GS; Bertoletti A; Pilli M; Cavallo C; Cavalli A; Urbani S; Boehme R; Panebianco R; Fiaccadori F; Ferrari C
Hepatology; 2001 Apr; 33(4):963-71. PubMed ID: 11283861
[TBL] [Abstract][Full Text] [Related]
2. [HBV-specific CD8+ T cells for sustained HBeAg seroconversion after lamivudine therapy].
Lee CK; Han KH; Suh JH; Cho YS; Won SY; Chon CY; Moon YM; Park IS
Korean J Hepatol; 2005 Mar; 11(1):34-42. PubMed ID: 15788883
[TBL] [Abstract][Full Text] [Related]
3. Recovery of functional cytotoxic T lymphocytes during lamivudine therapy by acquiring multi-specificity.
Kondo Y; Asabe S; Kobayashi K; Shiina M; Niitsuma H; Ueno Y; Kobayashi T; Shimosegawa T
J Med Virol; 2004 Nov; 74(3):425-33. PubMed ID: 15368520
[TBL] [Abstract][Full Text] [Related]
4. The impact of HBV-DNA fluctuations on virus-specific CD8+ T cells in HBeAg+ chronic hepatitis B patients treated with a steroid and lamivudine.
Gotto J; Webster GJ; Brown D; Jenkins J; Dusheiko GM; Bertoletti A
J Viral Hepat; 2006 Jun; 13(6):415-25. PubMed ID: 16842445
[TBL] [Abstract][Full Text] [Related]
5. [Direct analysis of HBV-specific CD8+ lymphocyte by tetrameric HLA-A2/core 18-27 complex in chronic Hepatitis B].
Lee CK; Suh JH; Cho YS; Han KH; Chung JB; Chon CY; Moon YM
Taehan Kan Hakhoe Chi; 2002 Jun; 8(2):139-48. PubMed ID: 12499799
[TBL] [Abstract][Full Text] [Related]
6. Intrahepatic CD8 T-lymphocytes and HBV core expression in relation to response to antiviral therapy for chronic hepatitis B patients.
Tang TJ; de Man RA; Kusters JG; Kwekkeboom J; Hop WC; van der Molen RG; Schalm SW; Janssen HL
J Med Virol; 2004 Feb; 72(2):215-22. PubMed ID: 14695662
[TBL] [Abstract][Full Text] [Related]
7. A method to increase tetramer staining efficiency of CD8+ T cells with MHC-peptide complexes: therapeutic applications in monitoring cytotoxic T lymphocyte activity during hepatitis B and C treatment.
Tsai SL; Lee TH; Chien RN; Liao SK; Lin CL; Kuo GC; Liaw YF
J Immunol Methods; 2004 Feb; 285(1):71-87. PubMed ID: 14871536
[TBL] [Abstract][Full Text] [Related]
8. Dynamic programmed death 1 expression by virus-specific CD8 T cells correlates with the outcome of acute hepatitis B.
Zhang Z; Zhang JY; Wherry EJ; Jin B; Xu B; Zou ZS; Zhang SY; Li BS; Wang HF; Wu H; Lau GK; Fu YX; Wang FS
Gastroenterology; 2008 Jun; 134(7):1938-49, 1949.e1-3. PubMed ID: 18455515
[TBL] [Abstract][Full Text] [Related]
9. A multi-center open study to determine the effect of lamivudine on HBV DNA clearance and to assess the safety of the regimen in patients with chronic hepatitis B infection.
Mazur W; Król F; Cianciara J; Nazzal K; Gładysz A; Juszczyk J; Bolewska B; Adamek J; Czajka B; Swietek K; Kryczka W; Gonciarz Z
Med Sci Monit; 2002 Apr; 8(4):CR257-62. PubMed ID: 11951067
[TBL] [Abstract][Full Text] [Related]
10. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.
Leung NW; Lai CL; Chang TT; Guan R; Lee CM; Ng KY; Lim SG; Wu PC; Dent JC; Edmundson S; Condreay LD; Chien RN;
Hepatology; 2001 Jun; 33(6):1527-32. PubMed ID: 11391543
[TBL] [Abstract][Full Text] [Related]
11. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion.
Evans A; Riva A; Cooksley H; Phillips S; Puranik S; Nathwani A; Brett S; Chokshi S; Naoumov NV
Hepatology; 2008 Sep; 48(3):759-69. PubMed ID: 18697210
[TBL] [Abstract][Full Text] [Related]
12. Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity.
Rigopoulou EI; Suri D; Chokshi S; Mullerova I; Rice S; Tedder RS; Williams R; Naoumov NV
Hepatology; 2005 Nov; 42(5):1028-36. PubMed ID: 16250037
[TBL] [Abstract][Full Text] [Related]
13. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
[TBL] [Abstract][Full Text] [Related]
14. High frequency of functional anti-YMDD and -mutant cytotoxic T lymphocytes after in vitro expansion correlates with successful response to lamivudine therapy for chronic hepatitis B.
Lin CL; Tsai SL; Lee TH; Chien RN; Liao SK; Liaw YF
Gut; 2005 Jan; 54(1):152-61. PubMed ID: 15591521
[TBL] [Abstract][Full Text] [Related]
15. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.
Moskovitz DN; Osiowy C; Giles E; Tomlinson G; Heathcote EJ
J Viral Hepat; 2005 Jul; 12(4):398-404. PubMed ID: 15985011
[TBL] [Abstract][Full Text] [Related]
16. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion.
Miailhes P; Trabaud MA; Pradat P; Lebouché B; Chevallier M; Chevallier P; Zoulim F; Trepo C
Clin Infect Dis; 2007 Sep; 45(5):624-32. PubMed ID: 17682999
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes of chronic hepatitis B patients with persistently detectable serum hepatitis B virus DNA during lamivudine therapy.
Kim JH; Yu SK; Seo YS; Yim HJ; Yeon JE; Park JJ; Kim JS; Bak YT; Lee CH; Byun KS
J Gastroenterol Hepatol; 2007 Aug; 22(8):1220-5. PubMed ID: 17532786
[TBL] [Abstract][Full Text] [Related]
18. Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers.
Kohmoto M; Enomoto M; Tamori A; Habu D; Takeda T; Kawada N; Sakaguchi H; Seki S; Shiomi S; Nishiguchi S
J Med Virol; 2005 Feb; 75(2):235-9. PubMed ID: 15602726
[TBL] [Abstract][Full Text] [Related]
19. Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppression.
Yeh CT; Hsu CW; Chen YC; Liaw YF
J Clin Virol; 2009 Jun; 45(2):114-8. PubMed ID: 19451024
[TBL] [Abstract][Full Text] [Related]
20. Effects of HBV gene variations on disease development and antiviral therapy for patients with chronic hepatitis B.
Chen JY; Wang LW; Sun XM; Gong ZJ
Hepatobiliary Pancreat Dis Int; 2005 Aug; 4(3):393-7. PubMed ID: 16109523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
